DIDinara Ilyasova

Dinara Ilyasova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dinara Ilyasova has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • A. N. Stetsyuk

    Department of Oncology, Radiotherapy and Reconstructive Surgery, Levshin Institute of Cluster Oncology, Sechenov First Moscow State Medical University, 119435 Moscow, Russia

    2 shared publications
  • Aida Gilyadova

    Department of Oncology, Radiotherapy and Reconstructive Surgery, Levshin Institute of Cluster Oncology, Sechenov First Moscow State Medical University, 119435 Moscow, Russia

    2 shared publications
  • Anna Alyasova

    Department of Oncology, Radiotherapy and Reconstructive Surgery, Levshin Institute of Cluster Oncology, Sechenov First Moscow State Medical University, 119435 Moscow, Russia

    2 shared publications
  • Ekaterina Rostislavova

    Department of Oncology, Radiotherapy and Reconstructive Surgery, Levshin Institute of Cluster Oncology, Sechenov First Moscow State Medical University, 119435 Moscow, Russia

    2 shared publications
  • Igor Reshetov

    Department of Oncology, Radiotherapy and Reconstructive Surgery, N.V. Sklifosovsky Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia

    2 shared publications
  • Kanamat Efendiev

    Department of Medical Photonics, Prokhorov General Physics Institute of the Russian Academy of Sciences, 119991 Moscow, Russia

    2 shared publications

Latest Publications

  • Open Access

    Current Approaches and Emerging Strategies in the Treatment of Peritoneal Carcinomatosis

    by Anna Alyasova, Kanamat Efendiev, Igor Reshetov, Dinara Ilyasova, Olga Shpileva, Victor Loschenov, Vladimir Makarov, Evgenia Zakharova, Pavel Karalkin, Yulia Agakina, et al.

    Peritoneal carcinomatosis (PC) is a common, prognostically unfavorable manifestation of advanced gastrointestinal and gynecological malignancies whose treatment is constrained by the blood-peritoneal barrier, which limits drug penetration even when cytoreductive surgery is combined with systemic chemotherapy. This review evaluates current intraperitoneal treatment modalities and emerging technologies for overcoming this limitation, based on recent clinical trials and meta-analyses identified through Scopus and PubMed. We sequentially examine conventional intraperitoneal chemotherapy (IPC); hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian, gastric, and colorectal cancers, with attention to patient selection and the peritoneal cancer index as determinants of survival benefit; pressurized intraperitoneal aerosol chemotherapy (PIPAC) and its electrostatic precipitation variant (ePIPAC); and photodynamic and photothermal therapy for tumor treatment. Novel strategies are also discussed, including IPC combined with immune checkpoint inhibitors, optical dosimetry, and nanomedicine-based drug delivery as tools for improving treatment precision. Overall, management of PC is transitioning toward a personalized, multimodal approach: HIPEC and PIPAC provide standardized platforms for regional therapy, but future progress depends on integrating advanced drug delivery systems, immunotherapy, and real-time intraoperative monitoring, with standardization of protocols through large multicenter trials remaining a priority for translating these modalities into clinical practice.


  • Open Access

    Photodynamic Therapy Combined with Anticancer Drug Therapy in the Treatment of Malignant Neoplasms

    by Igor Reshetov, Anna Alyasova, Olga Shpileva, Pavel Karalkin, Kanamat Efendiev, Daria Pominova, Victor Loschenov, Dinara Ilyasova, Yulia Agakina, Aida Gilyadova, et al.

    Background: Photodynamic therapy (PDT) has emerged as a powerful minimally invasive modality for cancer treatment. However, its efficacy as a monotherapy is often limited by oxygen dependence and limited light penetration. Combining PDT with systemic anticancer drug therapies offers a promising strategy to achieve synergistic effects and overcome resistance. Objective: This review aims to provide a systematic analysis of the mechanisms and clinical potential of combining PDT with chemotherapy, targeted therapy, and immunotherapy, focusing on recent advancements and nanotechnology-based delivery systems. Methods: A comprehensive literature search was performed using PubMed and Scopus databases. The analysis focused on peer-reviewed studies published over the last 10 years addressing synergistic molecular pathways, co-delivery nanoplatforms, and clinical trial outcomes. Results: The combination of PDT with chemotherapy enhances drug accumulation via vascular photosensitization and can overcome multi-drug resistance. Integration with immunotherapy, particularly immune checkpoint inhibitors and tumor vaccines, triggers immunogenic cell death (ICD), leading to systemic antitumor responses. Nanotechnology provides a versatile platform for the targeted co-delivery of photosensitizers and pharmacological agents, significantly reducing systemic toxicity. Conclusions: Combined PDT–drug regimens demonstrate superior therapeutic efficacy compared to monotherapies. Future clinical translation requires the standardization of dosimetry and the development of multifunctional nanomedicines to enable personalized treatment protocols.


  • Molecular and genetic aspects of endometrial cancer prognosis

    by A.V. Gilyadova, A.A. Ishchenko, A.I. Ishchenko, E.M. Kulikova, N.V. Petukhova, A.E. Kiseleva, O.V. Shpileva, A.S. Fatyanova, D.B. Ilyasova, E.A. Rostislavova, et al.

    Endometrial cancer is one of the most common malignant neoplasms in female patients. Despite the latest advances in medicine, the incidence of this disease is increasing every year. The growing use of molecular and genetic profiling and immune checkpoint inhibitors is aimed at reducing morbidity, improving prognosis and survival outcomes, especially for patients with hypermutated mismatch repair deficiency/microsatellite instability and an ultra-mutated profile. Risk factors determined by histological examination include morphology, stage and degree of differentiation according to the FIGO classification, depth of myometrial invasion, and lymphovascular space invasion. They are useful to identify the need for postoperative treatment to reduce the risk of recurrence. Moreover, the leading factor influencing the prognosis of the disease is the involvement of lymph nodes in the malignant process. On the one hand, many retrospective studies have shown the positive effect of lymphadenectomy on recurrence-free survival in patients. On the other hand, this procedure may be followed by certain risks and complications, which casts doubt on the consideration of this treatment method as the gold standard for low-grade tumors. Additional data based on molecular and genomic characteristics of endometrial tumors are needed to assess the status of lymph nodes, and the inclusion of molecular classification in the traditional clinical and pathological staging system for endometrial cancer is becoming increasingly important and critical. Objective. To analyze literature data on the current state and assess the diagnostic significance of known molecular and genetic predictors in relation to the evaluation of the risk of endometrial cancer progression. Key words: uterine cancer, endometrioid adenocarcinoma, molecular predictors, genetic profiling, lymphadenectomy, microRNA, tumor marker